ArticleClinical & experimental metastasis2009
Epigenetic contributions to cancer metastasis.
Article in Clinical & experimental metastasis, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- DNA methylation markers for risk of metastasis in a cohort of men with localized prostate cancer.Epigenetics · 2024Article
- Genome-wide methylation profiling of diagnostic tumor specimens identified DNA methylation markers associated with metastasis among men with untreated localized prostate cancer.Cancer medicine · 2023Article
- Epigenetic modification regulates tumor progression and metastasis through EMT (Review).International journal of oncology · 2022Review
- Epigenetic Modifications in Tumor-Associated Macrophages: A New Perspective for an Old Foe.Frontiers in immunology · 2022Review
- The natural adaptive evolution of cancer: The metastatic ability of cancer cells.Bosnian journal of basic medical sciences · 2020Review
- Positively selected enhancer elements endow osteosarcoma cells with metastatic competence.Nature medicine · 2018Article
- Grifolin directly targets ERK1/2 to epigenetically suppress cancer cell metastasis.Oncotarget · 2015Article
- IRX1 hypomethylation promotes osteosarcoma metastasis via induction of CXCL14/NF-κB signaling.The Journal of clinical investigation · 2015Article
- Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.Journal of cancer research and clinical oncology · 2015Article
- Genome-Wide Scan for Methylation Profiles in Keloids.Disease markers · 2015Article
- Pluronics and MDR reversal: an update.Molecular pharmaceutics · 2014Review
- Association of COX2 gene hypomethylation with intestinal type gastric cancer in samples of patients from northern Brazil.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer.Oncogene · 2013Article
- Effect of doxorubicin/pluronic SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell markers in murine leukemia.PloS one · 2013Article
- LRpath analysis reveals common pathways dysregulated via DNA methylation across cancer types.BMC genomics · 2012Article
- Article
- Article
- Mechanisms of cancer cell metastasis to the bone: a multistep process.Future oncology (London, England) · 2011Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The molecular basis of cancer encompasses both genetic and epigenetic alterations. These epigenetic changes primarily involve global DNA methylation changes in the form of widespread loss of methylation along with concurrent hypermethylation events in gene regulatory regions that can repress tissue-specific gene expression. Increasingly, the importance of these epigenetic changes to the metastatic process is being realized. Cells may acquire an epi-genotype that permits their dissemination from the primary tumour mass or the ability to survive and proliferate at a secondary tissue site. These epigenetic changes may be cancer-type specific, or in some cases may involve a common target gene providing a selective advantage to multiple metastatic cell types. In this review, I examine the growing volume of literature related to the epigenetic contributions to cancer metastasis. I discuss the functional importance of these epigenetic phenomena and how new epigenetic biomarkers may permit the identification of diagnostic signatures of metastasis and the development of new cancer therapies.
Indexed as
Identifiers
18386135What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.